Stephen Appezzato

A new BGH survey shows some large employers are pulling back on GLP-1 weight-loss coverage in 2027 as rising costs and utilization outpace anticipated savings.

In this week's Pharma Pulse, USP's annual shortages report reveals a sharp rise in drug discontinuations, J&J and Roche commit billions to protein degrader platforms, and more.

X-Therma's end-to-end biopreservation system promises to push storage and transport window from hours to five days, without freezing or toxic additives.

As specialty drug spend tops 50% of pharmacy costs, health system specialty pharmacies are evolving from dispensers into longitudinal care management partners.

Specialty pharmacies are moving beyond the dispense—layering SDOH screening, adherence coaching, and chronic disease management into the patient journey.

Danny Williams breaks down direct-to-patient distribution and his outlook on where pharma 3PLs are headed over the next five years.

After adding 160 more drugs, TrumpRx tops 800 prescription offerings. Here's what the latest MFN-driven expansion means for pricing and access.

Danny Williams discusses how AI has moved from experimental pilots to full operational deployment across supply chain functions, and how cell and gene therapies are reshaping the logistics industry.

4flow's Natalia Andreyeva breaks down the persistent planning failures driving AI adoption in pharma supply chains.

A new CMS demonstration launching July 1 will offer eligible Part D beneficiaries access to branded obesity drugs at a $50 copay. Here's what manufacturers, payers, and pharmacies need to know.

CMS's Medicare GLP-1 Bridge launches July 1, giving eligible Part D beneficiaries access to branded obesity drugs at a $50 copay — outside the standard Part D benefit.

EVERSANA's Danny Williams breaks down the most consequential operational shifts in pharma 3PL over the past five years, from full-pallet distribution to integrated commercialization support for complex, targeted therapies.

In this week's Pharma Pulse, a Bluesight survey flags hospital pharmacy's top concerns, the Wegovy pill is introduced to the UAE, and more.

Novo Nordisk's UAE launch of the Wegovy pill signals a new phase of oral GLP-1 commercialization, with major implications for pharma distribution, channel strategy, and international market access.

Erez Israeli explains how Dr. Reddy's approached commercial readiness for its generic semaglutide launch in Canada and what vertical integration in peptide manufacturing means for the GLP-1 market.

Cencora will support US distribution of Kite's Yescarta and Tecartus, reducing administrative burdens and expanding CAR T-cell therapy access at authorized treatment centers.

Cameron Olig explains how transparency and direct access models can help pharma close the gap between drug pricing, distribution and the patient.

ThermoSafe expands US VIP manufacturing amid surging biologics demand and growing pressure to reduce overseas cold chain packaging risk.

The PBM’s updated commercial formularies reflect negotiated pricing progress with manufacturers.

In this week's Pharma Pulse, House committees advance key legislation targeting PBM kickbacks and pharmacy access, Macfarlane Packaging partners with eutecma to bring modular cold chain solutions to the UK, and more.

Intelliguard and Accucold have launched an RFID-enabled refrigerated cabinet to improve hospital medication tracking, visibility, and cold-chain control.

Generic drug shortages may seem sudden, but they stem from ongoing pressures in manufacturing, pricing, and global supply chains, especially in hospitals.

Kieran Daly discusses how adherence programs can improve patient outcomes, support specialty pharmacy performance, and reduce healthcare costs.

BMS will deploy enterprise AI across functions to streamline workflows, structure field insights, and improve HCP engagement and execution.

Tommy Bramley explains how real-world evidence is reshaping how specialty pharma demonstrates value — from trial design to payer negotiations and patient outcomes.

In this week's Pharma Pulse, the Trump administration expands TrumpRx to over 600 generics, the Supreme Court clears the way for long-term Medicare drug price negotiations, Eli Lilly moves deeper into genetic medicines with a $202 million acquisition, and the FDA loses more top leadership.

Rahul Mittal explains how execution infrastructure can help generics manufacturers improve hospital access, reduce delays, and strengthen coordination.

Rahul Mittal shows how execution infrastructure can improve access, cut delays, and strengthen coordination for generic drug manufacturers in hospitals.

The expansion of TrumpRx will increase price transparency and purchase options of generic drugs for cash-paying patients.

There is never a quiet moment to step into a new role, and joining Pharmaceutical Commerce as editor has been no exception.